Presight Sensei Co-Invest Fund, L.P. 4
4 · Sensei Biotherapeutics, Inc. · Filed Feb 27, 2023
Insider Transaction Report
Form 4
Apeiron Investment Group Ltd.
10% Owner
Transactions
- Purchase
Common Stock
2023-02-23$1.60/sh+1,100$1,763→ 2,485,923 total(indirect: By Apeiron Investment Group Ltd.) - Purchase
Common Stock
2023-02-23$1.61/sh+1,100$1,777→ 2,484,823 total(indirect: By Apeiron Investment Group Ltd.)
Holdings
- 955,738(indirect: By Presight Sensei Co-Invest Fund, L.P.)
Common Stock
Footnotes (3)
- [F1]This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- [F2]Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.
- [F3]Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest.